Association of TLR3 and TLR5 Gene Polymorphism with Schizophrenia

Öyküm Genç Akar; Sevim Karakaş Çelik; Güliz Şenormancı; Ayşe Semra Demir Akça; Ömer Şenormancı

doi:10.18521/ktd.1849655

EN

Association of TLR3 and TLR5 Gene Polymorphism with Schizophrenia

Abstract

Aim: Schizophrenia is a neuropsychiatric disorder whose cause and pathogenesis have not been fully clarified. It affects approximately 1% of society. Despite the lack of knowledge about the role of TLRs in the etiology of schizophrenia, studies on prenatal infection, inflammation, obstetric complications, oxidative/nitrosative stress, neurodegeneration, and cognitive function suggest that TLRs may be involved in the pathogenesis of schizophrenia. To the best of our knowledge, no studies have investigated the association of TLR3 rs3775291 and TLR5 rs1861172 polymorphisms with schizophrenia Therefore, the aim of this study was to determine whether there is an association between schizophrenia and TLR3 and TLR5 gene polymorphisms.

Material and Methods: A total of 140 patients diagnosed with schizophrenia and 104 healthy individuals without any neuropsychiatric disease participated in our study. TLR3 rs3775291 and TLR5 rs1861172 gene polymorphisms were selected using PolyPhen 2.0, MirSNP, and SIFT databases. Polymorphisms were detected using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.

Results: The genotype distributions of rs3775291 (CC: 61.4%, CG: 31.4%, GG: 7.1%; p=0.494) and rs1861172 (AA: 30.7%, AG: 55.0%, GG: 14.3%; p=0.875) in the schizophrenia group were comparable to those in the control group (rs3775291: 53.8%, 37.5%, 8.7%; p=0.250; rs1861172: 33.7%, 51.9%, 14.4%, p=0.756), with no statistically significant differences observed (p > 0.05).

Conclusion: This study is the first to investigate the association between schizophrenia and the rs3775291 and rs1861172 polymorphisms. In conclusion, no statistically significant difference was observed between the groups. Considering the ethnic diversity in schizophrenia, conducting similar studies in other populations would be informative.

Keywords

References

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-858. doi:10.1016/S0140-6736(18)32279-7.
Abarca-Merlin DM, Martínez-Durán JA, Medina-Pérez JD, Rodríguez-Santos G, Alvarez-Arellano L. From immunity to neurogenesis: toll-like receptors as versatile regulators in the nervous system. Int J Mol Sci. 2024;25(11):5711. doi:10.3390/ijms25115711.
Chang SH, Chiang SY, Chiu CC, Tsai CC, Tsai HH, Huang CY, et al. Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia. Psychiatry Res. 2011;187(3):341-6. doi:10.1016/j.psychres.2010.04.049.
De Miranda J, Yaddanapudi K, Hornig M, Villar G, Serge R, Lipkin WI. Induction of Toll-like receptor 3-mediated immunity during gestation inhibits cortical neurogenesis and causes behavioral disturbances. mBio. 2010;1(4):e00176-10. doi:10.1128/mBio.00176-10.
Espino A, El Costa H, Tabiasco J, Al-Daccak R, Jabrane-Ferrat N. Innate immune response to viral infections at the maternal-fetal interface in human pregnancy. Front Med (Lausanne). 2021;8:674645. doi:10.3389/fmed.2021.674645.
Duan T, Du Y, Xing C, Wang HY, Wang RF. Toll-like receptor signaling and its role in cell-mediated immunity. Front Immunol. 2022;13:812774. doi:10.3389/fimmu.2022.812774.
Patlola SR, Donohoe G, McKernan DP. Counting the toll of inflammation on schizophrenia—a potential role for toll-like receptors. Biomolecules. 2023;13(8):1188. doi:10.3390/biom13081188.
Crisafulli C, Drago A, Calabrò M, Spina E, Serretti A. A molecular pathway analysis informs the genetic background at risk for schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2015;59:21-30. doi:10.1016/j.pnpbp.2014.12.009.

Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-9. doi:10.1038/nmeth0410-248.
Liu C, Zhang F, Li T, Lu M, Wang L, Yue W, et al. MirSNP, a database of polymorphisms altering miRNA target sites, identifies miRNA-related SNPs in GWAS SNPs and eQTLs. BMC Genomics. 2012;13:661. doi: 10.1186/1471-2164-13-661.
Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13):3812-4. doi:10.1093/nar/gkg509.
Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics. 2012;13:134. doi:10.1186/1471-2105-13-134.
Marshall OJ. PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR. Bioinformatics. 2004;20(15):2471-2. doi:10.1093/bioinformatics/bth254.
Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47(D1):D155-62. doi:10.1093/nar/gky1141.
Wang P, Cao T, Chen J, Jiang Y, Wang C, Waddington JL, et al. D2 receptor-mediated miRNA-143 expression is associated with the effects of antipsychotic drugs on phencyclidine-induced schizophrenia-related locomotor hyperactivity and with Neuregulin-1 expression in mice. Neuropharmacology. 2019;157:107675. doi:10.1016/j.neuropharm.2019.107675.
Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86-97. doi:10.1016/S0140-6736(15)01121-6.
Ermakov EA, Melamud MM, Buneva VN, Ivanova SA. Immune system abnormalities in schizophrenia: an integrative view and translational perspectives. Front Psychiatry. 2022;13:880568. doi:10.3389/fpsyt.2022.880568.
Dong S, Schneider-Thoma J, Bighelli I, Siafis S, Wang D, Burschinski A, et al. A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2024;274(4):917-28. doi:10.1007/s00406-023-01654-2.
Okun E, Griffioen KJ, Mattson MP. Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci. 2011;34(5):269-81. doi:10.1016/j.tins.2011.02.005.
Carty M, Reinert L, Paludan SR, Bowie AG. Innate antiviral signalling in the central nervous system. Trends Immunol. 2014;35(2):79-87. doi:10.1016/j.it.2013.10.012.
Cameron JS, Alexopoulou L, Sloane JA, DiBernardo AB, Ma Y, Kosaras B, et al. Toll-like receptor 3 is a potent negative regulator of axonal growth in mammals. J Neurosci. 2007;27(47):13033-41. doi:10.1523/JNEUROSCI.4290-06.2007.
Deeba E, Koptides D, Lambrianides A, Pantzaris M, Krashias G, Christodoulou C. Complete sequence analysis of human toll-like receptor 3 gene in natural killer cells of multiple sclerosis patients. Mult Scler Relat Disord. 2019;33:100-6. doi:10.1016/j.msard.2019.05.027.
McKernan DP, Dennison U, Gaszner G, Cryan JF, Dinan TG. Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. Transl Psychiatry. 2011;1(8):e36. doi:10.1038/tp.2011.37.
Kang WS, Park JK, Lee SM, Kim SK, Park HJ, Kim JW. Association between genetic polymorphisms of Toll-like receptor 2 (TLR2) and schizophrenia in the Korean population. Gene. 2013;526(2):182-6. doi:10.1016/j.gene.2013.04.058.
Kozłowska E, Agier J, Wysokiński A, Łucka A, Sobierajska K, Brzezińska-Błaszczyk E. The expression of toll-like receptors in peripheral blood mononuclear cells is altered in schizophrenia. Psychiatry Res. 2019;272:540-50. doi:10.1016/j.psychres.2018.12.138.

Details

Primary Language

English

Subjects

Health Services and Systems (Other)

Journal Section

Research Article

Authors

Öyküm Genç Akar ^*
0000-0002-9805-2663
Türkiye

Sevim Karakaş Çelik
0000-0003-0505-7850
Türkiye

Güliz Şenormancı
0000-0001-8000-0075
Türkiye

Ayşe Semra Demir Akça
0000-0002-2092-656X
Türkiye

Ömer Şenormancı
0000-0002-1407-4911
Türkiye

Publication Date

October 27, 2026

Submission Date

January 1, 2026

Acceptance Date

July 24, 2026

Published in Issue

Year 2026 Volume: 18 Number: 3

DOI

https://doi.org/10.18521/ktd.1849655

IZ

https://izlik.org/JA33JM78LR

Cite

RIS / Bibtex

APA

Genç Akar, Ö., Karakaş Çelik, S., Şenormancı, G., Demir Akça, A. S., & Şenormancı, Ö. (2026). Association of TLR3 and TLR5 Gene Polymorphism with Schizophrenia. Konuralp Medical Journal, 18(3), 191-199. https://doi.org/10.18521/ktd.1849655

AMA

1.Genç Akar Ö, Karakaş Çelik S, Şenormancı G, Demir Akça AS, Şenormancı Ö. Association of TLR3 and TLR5 Gene Polymorphism with Schizophrenia. Konuralp Medical Journal. 2026;18(3):191-199. doi:10.18521/ktd.1849655

Chicago

Genç Akar, Öyküm, Sevim Karakaş Çelik, Güliz Şenormancı, Ayşe Semra Demir Akça, and Ömer Şenormancı. 2026. “Association of TLR3 and TLR5 Gene Polymorphism With Schizophrenia”. Konuralp Medical Journal 18 (3): 191-99. https://doi.org/10.18521/ktd.1849655.

EndNote

Genç Akar Ö, Karakaş Çelik S, Şenormancı G, Demir Akça AS, Şenormancı Ö (October 1, 2026) Association of TLR3 and TLR5 Gene Polymorphism with Schizophrenia. Konuralp Medical Journal 18 3 191–199.

IEEE

[1]Ö. Genç Akar, S. Karakaş Çelik, G. Şenormancı, A. S. Demir Akça, and Ö. Şenormancı, “Association of TLR3 and TLR5 Gene Polymorphism with Schizophrenia”, Konuralp Medical Journal, vol. 18, no. 3, pp. 191–199, Oct. 2026, doi: 10.18521/ktd.1849655.

ISNAD

Genç Akar, Öyküm - Karakaş Çelik, Sevim - Şenormancı, Güliz - Demir Akça, Ayşe Semra - Şenormancı, Ömer. “Association of TLR3 and TLR5 Gene Polymorphism With Schizophrenia”. Konuralp Medical Journal 18/3 (October 1, 2026): 191-199. https://doi.org/10.18521/ktd.1849655.

JAMA

1.Genç Akar Ö, Karakaş Çelik S, Şenormancı G, Demir Akça AS, Şenormancı Ö. Association of TLR3 and TLR5 Gene Polymorphism with Schizophrenia. Konuralp Medical Journal. 2026;18:191–199.

MLA

Genç Akar, Öyküm, et al. “Association of TLR3 and TLR5 Gene Polymorphism With Schizophrenia”. Konuralp Medical Journal, vol. 18, no. 3, Oct. 2026, pp. 191-9, doi:10.18521/ktd.1849655.

Vancouver

1.Öyküm Genç Akar, Sevim Karakaş Çelik, Güliz Şenormancı, Ayşe Semra Demir Akça, Ömer Şenormancı. Association of TLR3 and TLR5 Gene Polymorphism with Schizophrenia. Konuralp Medical Journal. 2026 Oct. 1;18(3):191-9. doi:10.18521/ktd.1849655